In phase I/II clinical studies for NPC, NKTL and HL patients, adoptive transfer of CTLs specifically recognizing LMP1, LMP2 or EBNA1 has shown promising antitumour activity [46,52,53,54]. This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.